Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pliant Therapeutics, Inc. (PLRX : NSDQ)
 
 • Company Description   
Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO, Calif.

Number of Employees: 91

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.96 Daily Weekly Monthly
20 Day Moving Average: 253,769 shares
Shares Outstanding: 36.17 (millions)
Market Capitalization: $179.40 (millions)
Beta: 1.13
52 Week High: $33.95
52 Week Low: $3.97
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.21% -24.67%
12 Week -48.60% -42.23%
Year To Date -63.26% -55.12%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
260 LITTLEFIELD AVENUE
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-481-6770
fax: -
ir@pliantrx.com http://pliantrx.com
 
 • General Corporate Information   
Officers
Bernard Coulie - Chief Executive Officer;President;
Hoyoung Huh - Chairman of the Board; Director
Keith Cummings - Chief Financial Officer
Suzanne Bruhn - Director
Gayle Crowell - Director

Peer Information
Pliant Therapeutics, Inc. (CORR.)
Pliant Therapeutics, Inc. (RSPI)
Pliant Therapeutics, Inc. (CGXP)
Pliant Therapeutics, Inc. (BGEN)
Pliant Therapeutics, Inc. (GTBP)
Pliant Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 729139105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 36.17
Most Recent Split Date: (:1)
Beta: 1.13
Market Capitalization: $179.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.35 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.03
Price/Cash Flow: -
Price / Sales: 26.99
EPS Growth
vs. Year Ago Period: -21.87%
vs. Previous Quarter: -14.71%
Sales Growth
vs. Year Ago Period: -42.55%
vs. Previous Quarter: -37.52%
ROE
03/31/22 - -48.97
12/31/21 - -41.94
09/30/21 - -36.28
ROA
03/31/22 - -45.15
12/31/21 - -39.44
09/30/21 - -34.61
Current Ratio
03/31/22 - 10.12
12/31/21 - 12.44
09/30/21 - 17.68
Quick Ratio
03/31/22 - 10.12
12/31/21 - 12.44
09/30/21 - 17.69
Operating Margin
03/31/22 - -1,542.15
12/31/21 - -1,284.51
09/30/21 - -914.12
Net Margin
03/31/22 - -1,542.15
12/31/21 - -1,284.51
09/30/21 - -914.12
Pre-Tax Margin
03/31/22 - -1,542.15
12/31/21 - -1,284.51
09/30/21 - -914.12
Book Value
03/31/22 - 4.81
12/31/21 - 5.52
09/30/21 - 6.13
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©